[Pharmaco-economic evaluation ("cost-benefit" analysis) of gastroesophageal reflux treatment].
Guseĭnzade
M G
MG
Li
I A
IA
Lazebnik
L B
LB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D007902:Length of Stay / Q000191:economics / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009031:Moscow / Q000453:epidemiology; D010045:Outpatients / Q000706:statistics & numerical data; D013997:Time Factors; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents